Open AccessClinical efficiency of antioxidant therapy in patients with liver cirrhosis and acute blood loss
Author(s) -
Д. А. Евсеенко,
З. А. Дундаров
Publication year - 2021
Publication title -
problemy zdorovʹâ i èkologii
Language(s) - English
Resource type - Journals
eISSN - 2708-6011
pISSN - 2220-0967
DOI - 10.51523/2708-6011.2021-18-1-10
Subject(s) - uric acid , medicine , cirrhosis , antioxidant , gastroenterology , hemoglobin , lymphocyte , biochemistry , biology
Objective: to determine the clinical efficiency of antioxidant therapy in patients with liver cirrhosis and acute blood loss. Material and methods. The study included 286 patients with liver cirrhosis and acute blood loss of varying degrees of severity. The patients were divided into two series of studies. In the first series, the patients received the therapy according to the clinical diagnostic and treatment protocols, in the second series 1 according to the same protocols in combination with an intravenous administration of the antioxidant complexes “Reamberin” and “Fluimucil”. After 48 hours from admission, the antioxidant status of blood serum, the blebbing index of lymphocytes, the concentration of uric acid, and the level of hemoglobin were analyzed. The indicators of the clinical efficiency of the treatment were determined: risk of absolute mortality, risk of relative mortality, the number needed to treat. Results. The blood serum of the patients from the first series of studies was characterized by pronounced prooxidant activity, high values of the lymphocyte blebbing index, and a small amount of uric acid, which was indicative of the development of oxidative stress. The mortality rate in this series of studies was 26.0 %. The patients of the second series of studies were characterized by pronounced antioxidant activity of blood serum, low values of the lymphocyte blebbing index, and high concentrations of uric acid, which indicated a decrease in the activity of systemic oxidation processes. The mortality rate in this series of studies was 18.2 %. The duration of the treatment decreased from 16.5 days (first series) to 13.0 days (second series). Conclusion. The combined use of the “Reamberin” and “Fluimucil” complexes as part of the therapy according to the clinical diagnostic and treatment protocols leads to a relief of oxidative stress in patients with liver cirrhosis complicated by acute blood loss. The blood serum of these patients is characterized by pronounced antioxidant activity, low values of the lymphocyte blebbing index, and a high concentration of uric acid, which reduces the risk for the development of multiple organ failure syndrome. This therapy decreases the mortality rate to 18.2 % and the duration of the treatment to 13.0 days.